<DOC>
	<DOCNO>NCT00659282</DOCNO>
	<brief_summary>This study conduct Asia , Europe , Japan North America . The aim observational study evaluate safety effectiveness use NovoMix® 30 26 week normal clinical practice , country participate study . The primary outcome incidence major hypoglycaemic event report serious adverse drug reaction condition hypoglycaemic event .</brief_summary>
	<brief_title>Observational Study Safety Effectiveness NovoMix® 30 Treatment Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Age accord approve label physician discretion Type 2 diabetes include newlydiagnosed subject never receive insulin insulin analogue Subjects previously enrol study Subjects unlikely comply protocol requirement Hypersensitivity biphasic insulin aspart excipients Women pregnant , breast feeding intention become pregnant within next 12 month</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>